Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 23
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
CES odontol ; 15(2): 69-70, jul.-dic. 2002.
Artigo em Espanhol | LILACS | ID: lil-468511

RESUMO

Desde febrero de 2001, la doctora Tatiana Botero profesora asociada de la Facultad de Odontología se encuentra trabajando como profesora visitante en la Facultad de Odontología de la Universidad de Michigan en Ann Arbor donde ha trabajado en el grupo de investigacion liderado por el doctor Jacque Nor, con quien recientemente presento en el Congreso de la IADR su trabajo “Bacterial LPS Enhances VEGF Expresión in dental Pulp Cells and Macrophages”. Después de más de 18 meses, la doctora Botero nos presenta una perspectiva de nuestra situación académica vista desde el exterior teniendo en consideración su destacada trayectoria académica en nuestro medio.


Assuntos
Educação em Odontologia , Educação Profissionalizante , Odontologia , Educação
2.
Neurology ; 57(2): 177-83, 2001 Jul 24.
Artigo em Inglês | MEDLINE | ID: mdl-11480424

RESUMO

Neurocysticercosis is the most common helminthic infection of the CNS but its diagnosis remains difficult. Clinical manifestations are nonspecific, most neuroimaging findings are not pathognomonic, and some serologic tests have low sensitivity and specificity. The authors provide diagnostic criteria for neurocysticercosis based on objective clinical, imaging, immunologic, and epidemiologic data. These include four categories of criteria stratified on the basis of their diagnostic strength, including the following: 1) absolute--histologic demonstration of the parasite from biopsy of a brain or spinal cord lesion, cystic lesions showing the scolex on CT or MRI, and direct visualization of subretinal parasites by funduscopic examination; 2) major--lesions highly suggestive of neurocysticercosis on neuroimaging studies, positive serum enzyme-linked immunoelectrotransfer blot for the detection of anticysticercal antibodies, resolution of intracranial cystic lesions after therapy with albendazole or praziquantel, and spontaneous resolution of small single enhancing lesions; 3) minor--lesions compatible with neurocysticercosis on neuroimaging studies, clinical manifestations suggestive of neurocysticercosis, positive CSF enzyme-linked immunosorbent assay for detection of anticysticercal antibodies or cysticercal antigens, and cysticercosis outside the CNS; and 4) epidemiologic--evidence of a household contact with Taenia solium infection, individuals coming from or living in an area where cysticercosis is endemic, and history of frequent travel to disease-endemic areas. Interpretation of these criteria permits two degrees of diagnostic certainty: 1) definitive diagnosis, in patients who have one absolute criterion or in those who have two major plus one minor and one epidemiologic criterion; and 2) probable diagnosis, in patients who have one major plus two minor criteria, in those who have one major plus one minor and one epidemiologic criterion, and in those who have three minor plus one epidemiologic criterion.


Assuntos
Neurocisticercose/diagnóstico , Humanos
3.
Metabolism ; 49(6): 790-3, 2000 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-10877208

RESUMO

Glucocorticoids have been reported to exert a marked effect on lipoprotein metabolism. Several studies have shown a potential risk of hyperlipidemia in patients under long-term glucocorticoid therapy. Current management of patients with congenital adrenal hyperplasia (CAH) includes the use of glucocorticoids to attenuate the increased production of undesirable adrenal hormones. A case-control study was designed to compare the serum lipid profiles of 14 patients with CAH under glucocorticoid therapy and 14 normal controls and to determine the characteristics of the profiles. A total of 9 patients (64.3%) had serum total cholesterol (TC) greater than 4.4 mmol/L (170 mg/dL), compared with 6 individuals in the control group (42.3%). Nine patients with CAH (64.3%) had serum triglycerides (TGs) more than 1.0 mmol/L (90 mg/dL), compared with only 2 in the control group (14.3%). Similarly, the mean serum TG was higher in the CAH group versus the controls, 1.33 mmol/L (118 mg/dL) versus 0.75 mmol/L (67 mg/dL), respectively. Serum low-density lipoprotein, (LDL-C) and high-density, lipoprotein (HDL-C) cholesterol were determined in 13 children with CAH and in the 14 controls. Nine CAH patients (69.2%) and 8 controls (57%) had LDL-C greater than 2.8 mmol/L (<110 mg/dL). For HDL-C, 2 children with CAH (15.4%) and 4 controls (28.6%) had levels less than 0.9 mmol/L (35 mg/dL). There were no significant differences for the cholesterol index, 0.24 for the controls and 0.22 for the CAH group. In the CAH group, the mean serum TG level and the percentage of individuals with TGs greater than 1.0 mmol/L were statistically significant compared with the controls. The mean serum TC and LDL-C, as well as the percentage of subjects with levels over the cutoff point, although slightly higher in the CAH group, were of no statistical significance. The results of this pilot study suggest that long-term glucocorticoid therapy in patients with CAH may induce abnormalities in the serum lipid profile characterized mainly by an increment in serum TGs.


Assuntos
Hiperplasia Suprarrenal Congênita/sangue , Lipídeos/sangue , Arteriosclerose/sangue , Estudos de Casos e Controles , Criança , Pré-Escolar , Colesterol/sangue , Colômbia , Feminino , Glucocorticoides/efeitos adversos , Glucocorticoides/uso terapêutico , Hispânico ou Latino , Humanos , Lactente , Lipoproteínas/sangue , Masculino , Fatores de Risco , Triglicerídeos/sangue
4.
J Pediatr ; 132(4): 612-8, 1998 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-9580758

RESUMO

OBJECTIVE: The objective of this study was to compare the clinical utility of a new bioassay for thyrotropin (TSH) receptor antibodies (Abs) with the conventional radioreceptor assay and with measurement of thyroid peroxidase Abs in the diagnosis of Graves disease in childhood. STUDY DESIGN: Serum samples obtained from 22 children and adolescents with Graves disease (19 hyperthyroid, 3 in remission), 13 children and adolescents with chronic lymphocytic thyroiditis, and 17 normal children in a control group were evaluated. RESULTS: TSH receptor Abs were detected by bioassay in 10 (91%) of 11 patients with active Graves disease but in 0 of 2 patients in remission, 0 of 13 normal members of the control group, and 0 of 11 patients with chronic lymphocytic thyroiditis including 1 with thyrotoxicosis. The sensitivity and specificity of TSH receptor Abs detected by radioreceptor assay studied in the same 11 patients and in an additional 11 patients was similar to bioassay. In contrast, thyroid peroxidase Abs were detected in only 12 (71%) of 17 patients with Graves disease but in 11 of 11 patients with chronic lymphocytic thyroiditis and in 0 of 17 members of the control group. CONCLUSION: Bioassay of TSH receptor Abs is both sensitive and specific for the diagnosis of active Graves disease in the young. When cost and simplicity are considered, however, bioassay offers no advantage over radioreceptor assay for initial diagnostic screening. Rather, bioassay for TSH receptor Abs may be useful in thyrotoxic patients who are negative initially in the radioreceptor assay or in treated patients whose clinical picture is discordant with results in the radioreceptor assay.


Assuntos
Autoanticorpos/análise , Doença de Graves/diagnóstico , Receptores da Tireotropina/imunologia , Adolescente , Animais , Bioensaio , Células CHO , Estudos de Casos e Controles , Criança , Pré-Escolar , Cricetinae , Feminino , Humanos , Iodeto Peroxidase/imunologia , Masculino , Radioimunoensaio , Ensaio Radioligante , Sensibilidade e Especificidade , Tireoidite Autoimune/diagnóstico , Transfecção
5.
Bull World Health Organ ; 74(6): 591-7, 1996.
Artigo em Inglês | MEDLINE | ID: mdl-9060219

RESUMO

A total of 120 semi-immune adult male malaria patients from an area of multidrug-resistant Plasmodium falciparum malaria were hospitalized for 42 days in Medellin, Colombia (an area of no malaria transmission), and treated with halofantrine in a double-blind, randomized, prospective clinical trial according to five different treatment schedules. Each patient was assigned to one of the following halofantrine schedules: I, one dose of 1000 mg; II, three doses of 500 mg; III, two doses of 500 mg; IV, three doses of 250 mg; and V, one dose of 750 mg. Best results (75% cure rate) were obtained with schedule II, although there was no statistically significant difference compared with the other schedules. A total of 46 patients experienced recrudescent malaria. Drug levels in plasma 72 hours after beginning treatment showed no statistically significant difference between relapsing and cured patients. Side-effects (mainly gastrointestinal) were uncommon and mild. Cardiotoxicity was studied by electrocardiogram. A mean prolongation of 28.5 ms (6.6 +/- 6.3% increase from baseline) was observed in the Q-Tc interval on day 1 of the trial.


Assuntos
Antimaláricos/uso terapêutico , Malária Falciparum/tratamento farmacológico , Fenantrenos/uso terapêutico , Adolescente , Adulto , Idoso , Antimaláricos/administração & dosagem , Antimaláricos/efeitos adversos , Criança , Colômbia , Método Duplo-Cego , Esquema de Medicação , Coração/efeitos dos fármacos , Humanos , Masculino , Pessoa de Meia-Idade , Fenantrenos/administração & dosagem , Fenantrenos/efeitos adversos , Recidiva
7.
J Pediatr ; 123(4): 590-2, 1993 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-8093122

RESUMO

In a 12-year-old girl, hyperglycemia and an elevated glycohemoglobin concentration developed after therapy with growth hormone for familial short stature. Both clinical and biochemical abnormalities disappeared after therapy was discontinued. The insulin response to an oral glucose tolerance test was abnormal 3 months after discontinuation of growth hormone; 18 months later, it remained delayed but was normal quantitatively.


Assuntos
Diabetes Mellitus Tipo 2/induzido quimicamente , Transtornos do Crescimento/tratamento farmacológico , Hormônio do Crescimento/efeitos adversos , Estatura , Criança , Diabetes Mellitus Tipo 2/diagnóstico , Feminino , Teste de Tolerância a Glucose , Transtornos do Crescimento/genética , Hormônio do Crescimento/uso terapêutico , Humanos , Proteínas Recombinantes/efeitos adversos , Proteínas Recombinantes/uso terapêutico
8.
Trans R Soc Trop Med Hyg ; 87(5): 576-7, 1993.
Artigo em Inglês | MEDLINE | ID: mdl-8266415

RESUMO

The efficacy of albendazole was evaluated in 20 Colombian patients with neurocysticercosis showing neurological symptoms. All had parenchymal non-enhancing cystic images by computerized tomography and a positive enzyme-linked immunosorbent assay for cysticercus antibodies in serum or cerebrospinal fluid. They stayed in hospital for 8 d during treatment with albendazole, 15 mg/kg/d in 2 divided doses, and were then followed for at least 6 months after treatment. The number of cysts was reduced by 50% after 6 months. In 7 (35%) all cysts disappeared, in 7 (35%) the number was reduced, and in the remaining 6 (30%) the number was unchanged. In the 13 patients who still had cysts at 6 months, 11 showed a moderate decrease in average cyst size and in 2 the size was unchanged. Side effects during treatment were observed in 60% of the cases, but only 3 required corticosteroids.


Assuntos
Albendazol/uso terapêutico , Encefalopatias/tratamento farmacológico , Cisticercose/tratamento farmacológico , Adolescente , Adulto , Idoso , Albendazol/administração & dosagem , Encefalopatias/parasitologia , Colômbia , Relação Dose-Resposta a Droga , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Fatores de Tempo , Resultado do Tratamento
9.
Infect Dis Clin North Am ; 7(3): 683-97, 1993 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-8254166

RESUMO

This article focuses on clinical issues of taeniasis and cysticercosis, including a comprehensive review of the clinical data, standard and latest chemotherapy, modern concepts of pathogenesis, conventional and advanced diagnostic tests, current epidemiology, and effective means of control. Fundamental parasitology is covered to familiarize physicians and scientists with the latest concepts of parasites.


Assuntos
Cisticercose , Teníase , Corticosteroides/uso terapêutico , Albendazol/uso terapêutico , Animais , Encéfalo/parasitologia , Encéfalo/patologia , Cisticercose/diagnóstico , Cisticercose/tratamento farmacológico , Cisticercose/epidemiologia , Humanos , Praziquantel/uso terapêutico , Teníase/diagnóstico , Teníase/tratamento farmacológico , Teníase/epidemiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA